# KVP Capital Advisors, LP

> Institutional holdings reported to the SEC as of Q2 2026 on Form 13F. CIK 1858198. Source: https://holderbook.com/funds/1858198-kvp-capital-advisors-lp/

- Reported value: $136.2M
- Positions: 35
- Weight of the ten largest: 57.4%
- Filed: 2026-08-13

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES I | [PRAX](https://holderbook.com/stocks/PRAX/) | $14.4M | 42,900 | 10.5% | 3 |
| WHITEHAWK THERAPEUTICS INC | [WHWK](https://holderbook.com/stocks/WHWK/) | $9.9M | 2,165,997 | 7.3% | 3 |
| ERASCA INC | [ERAS](https://holderbook.com/stocks/ERAS/) | $8.3M | 455,000 | 6.1% | 2 |
| TREVI THERAPEUTICS INC | [TRVI](https://holderbook.com/stocks/TRVI/) | $7.7M | 414,000 | 5.7% | 3 |
| SUTRO BIOPHARMA INC | [STRO](https://holderbook.com/stocks/STRO/) | $7.5M | 226,575 | 5.5% | 2 |
| TANGO THERAPEUTICS INC | [TNGX](https://holderbook.com/stocks/TNGX/) | $7.2M | 230,264 | 5.3% | 2 |
| MBX BIOSCIENCES INC | [MBX](https://holderbook.com/stocks/MBX/) | $6.7M | 121,524 | 4.9% | 3 |
| PROTAGONIST THERAPEUTICS INC | [PTGX](https://holderbook.com/stocks/PTGX/) | $6.5M | 53,000 | 4.8% | 3 |
| EDGEWISE THERAPEUTICS INC | [EWTX](https://holderbook.com/stocks/EWTX/) | $5.4M | 133,000 | 4.0% | 3 |
| TANDEM DIABETES CARE INC | [TNDM](https://holderbook.com/stocks/TNDM/) | $4.5M | 301,000 | 3.3% | 1 |
| DISC MEDICINE INC | [IRON](https://holderbook.com/stocks/IRON/) | $4.3M | 58,250 | 3.1% | 3 |
| SAVARA INC | [SVRA](https://holderbook.com/stocks/SVRA/) | $3.7M | 605,280 | 2.7% | 3 |
| ARRIVENT BIOPHARMA INC | [AVBP](https://holderbook.com/stocks/AVBP/) | $3.5M | 102,000 | 2.6% | 1 |
| INSMED INC | [INSM](https://holderbook.com/stocks/INSM/) | $3.0M | 28,497 | 2.2% | 3 |
| ACHIEVE LIFE SCIENCE INC | [ACHV](https://holderbook.com/stocks/ACHV/) | $3.0M | 462,355 | 2.2% | 3 |
| IDEAYA BIOSCIENCES INC | [IDYA](https://holderbook.com/stocks/IDYA/) | $3.0M | 79,700 | 2.2% | 2 |
| OCULAR THERAPEUTIX INC | [OCUL](https://holderbook.com/stocks/OCUL/) | $2.9M | 300,000 | 2.2% | 2 |
| AXSOME THERAPEUTICS INC | [AXSM](https://holderbook.com/stocks/AXSM/) | $2.9M | 12,000 | 2.2% | 3 |
| DESIGN THERAPEUTICS INC | [DSGN](https://holderbook.com/stocks/DSGN/) | $2.7M | 185,000 | 2.0% | 1 |
| UNITED THERAPEUTICS CORP DEL | [UTHR](https://holderbook.com/stocks/UTHR/) | $2.6M | 4,750 | 1.9% | 3 |
| SCHOLAR ROCK HLDG CORP | [SRRK](https://holderbook.com/stocks/SRRK/) | $2.5M | 45,000 | 1.8% | 3 |
| IMMIX BIOPHARMA INC | [IMMX](https://holderbook.com/stocks/IMMX/) | $2.4M | 230,423 | 1.7% | 3 |
| VIRIDIAN THERAPEUTICS INC | [VRDN](https://holderbook.com/stocks/VRDN/) | $2.3M | 125,000 | 1.7% | 2 |
| MINERALYS THERAPEUTICS INC | [MLYS](https://holderbook.com/stocks/MLYS/) | $2.3M | 84,168 | 1.7% | 1 |
| BRIGHT MINDS BIOSCIENCES INC | [DRUG](https://holderbook.com/stocks/DRUG/) | $2.2M | 31,813 | 1.6% | 2 |
| TRAVERE THERAPEUTICS INC | [TVTX](https://holderbook.com/stocks/TVTX/) | $2.2M | 39,000 | 1.6% | 3 |
| ZURA BIO LTD | [ZURA](https://holderbook.com/stocks/ZURA/) | $2.2M | 373,128 | 1.6% | 2 |
| ARTIVA BIOTHERAPEUTICS INC | [ARTV](https://holderbook.com/stocks/ARTV/) | $1.9M | 200,000 | 1.4% | 1 |
| NEKTAR THERAPEUTICS | [NKTR](https://holderbook.com/stocks/NKTR/) | $1.9M | 26,900 | 1.4% | 3 |
| COMPASS THERAPEUTICS INC | [CMPX](https://holderbook.com/stocks/CMPX/) | $1.7M | 771,000 | 1.2% | 2 |
| CABALETTA BIO INC | [CABA](https://holderbook.com/stocks/CABA/) | $1.6M | 505,431 | 1.2% | 3 |
| VERA THERAPEUTICS INC | [VERA](https://holderbook.com/stocks/VERA/) | $1.4M | 32,700 | 1.0% | 3 |
| EVOLUS INC | [EOLS](https://holderbook.com/stocks/EOLS/) | $1.0M | 150,000 | 0.8% | 1 |
| CELCUITY INC | [CELC](https://holderbook.com/stocks/CELC/) | $418.5K | 4,000 | 0.3% | 3 |
| VYNE THERAPEUTICS INC | [VYNE](https://holderbook.com/stocks/VYNE/) | $325.7K | 500,551 | 0.2% | 3 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q2 2026 | +23.2% | +14.8% | +8.4% | 81% |
| Q1 2026 | +9.0% | -4.6% | +13.7% | 100% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q2 2026 | $136.2M | 35 |
| Q1 2026 | $133.9M | 32 |
| Q4 2025 | $103.3M | 27 |